SynthesisFrontiers in microbiology2026
Bibliometric analysis of genetically engineered bacteria in tumor therapy.
Synthesis in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The utilization of bacteria for tumor treatment has a long-standing history. In recent years, with the continuous advancement of genetic engineering technologies, genetically engineered bacteria have attracted widespread attention in tumor-related research; however, to date, no bibliometric analysis has been reported for this field. In this study, bibliometric methods were employed to comprehensively evaluate the current research status, hotspots, and development trends of genetically engineered bacteria in the tumor field. Studies focusing on genetically engineered bacteria and tumors were retrieved from the Web of Science Core Collection (WOSCC) database and the Scopus database, and bibliometric and visualization analyses were conducted using R, VOSviewer, Scimago Graphica, and CiteSpace. Finally, we discuss the current limitations and challenges associated with the application of genetically engineered bacteria in the tumor field. Future research should focus on improving the safety, targeting capability, and clinical feasibility of engineered bacteria, as well as systematically investigating the interaction mechanisms among different therapeutic modalities, in order to promote the clinical translation of genetically engineered bacteria for tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.